Cellectis SA CLLS.OQ, CLLS.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2024
The Paris Ile-de-france-based company is expected to report a 228.5% increase in revenue to $5.4 million from $1.64 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cellectis SA is for a loss of 21 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cellectis SA is 6.50, above its last closing price of $1.78.
This summary was machine generated November 1 at 19:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments